In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 7, 2014, Pages 1856-1865

  Gaibani, Paolo ^a   Lombardo, Donatella ^a   Lewis, Russell E ^a   Mercuri, Marcella ^a   Bonora, Sonia ^a   Landini, Maria Paola ^a   Ambretti, Simone ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bacteraemia; Colistin resistance; K. pneumoniae; PAEs; Synergy assays

Indexed keywords

CARBAPENEMASE; COLISTIN; MEROPENEM; RIFAMPICIN; TEICOPLANIN; TIGECYCLINE; ANTIINFECTIVE AGENT; BACTERIAL DNA; BETA LACTAMASE; MINOCYCLINE;

AMPLICON; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BLOODSTREAM INFECTION; DRUG POTENTIATION; EPSILOMETER TEST; GENOTYPE; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; KINETICS; KLEBSIELLA PNEUMONIAE; KPC PRODUCING KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; POLYMERASE CHAIN REACTION; POSTANTIBIOTIC EFFECT; ANALOGS AND DERIVATIVES; BACTEREMIA; DNA SEQUENCE; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SECRETION (PROCESS);

ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; COLISTIN; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; GENOTYPE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; POLYMERASE CHAIN REACTION; RIFAMPIN; SEQUENCE ANALYSIS, DNA;

EID: 84902455414     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku065     Document Type: Article

References (42)

1. Kontopidou F, Giamarellou H, Katerelos P et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect 2013; 20: O117-23.
2. Daikos GL, Markogiannakis A, Souli M et al. Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective. Expert Rev Anti Infect Ther 2012; 10: 1393-404.
3. Munoz-Price LS, Poirel L, Bonomo RA et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13: 785-96.
4. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase producing Enterobacteriaceae. Emerg Infect Dis 2011; 17: 1791-8.
5. Canton R, Akova M, Carmeli Y et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012; 18: 413-31.
6. Glasner C, Albiger B, Buist G et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill 2013; 18: pii=20525.
7. Gaibani P, Ambretti S, Berlingeri A et al. Rapid increase of carbapenemase-producing Klebsiella pneumoniae strains in a large Italian hospital: surveillance period 1 March-30 September 2010. Euro Surveill 2011; 16: pii=19800.
8. Giani T, Pini B, Arena F et al. Epidemic diffusion of KPC carbapenemaseproducing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011. Euro Surveill 2013; 18: pii=20489.
9. Lee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob 2012; 11: 32.
10. Petrosillo N, Giannella M, Lewis R et al. Treatment of carbapenemresistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther 2013; 11: 159-77.
11. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPC): an emerging cause of multidrugresistant infection. J Antimicrob Chemother 2010; 65: 119-25.
12. Comandatore F, Sassera D, Ambretti S et al. Draft genome sequences of two multidrug resistant Klebsiella pneumoniae ST258 isolates resistant to colistin. Genome Announc 2013; 1: pii=e00113-12.
13. Comandatore F, Gaibani P, Ambretti S et al. Draft genome of Klebsiella pneumoniae sequence type 512, a multidrug-resistant strain isolated during a recent KPC outbreak in Italy. Genome Announc 2013; 1: pii=e00035-12.
14. Zarkotou O, Pournaras S, Tselioti P et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011; 17: 1798-803.
15. Tumbarello M, Viale P, Viscoli C et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55: 943-50.
16. Tascini C, Tagliaferri E, Giani T et al. Synergistic activity of colistin plus rifampicin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2013; 57: 3990-3.
17. EUCAST. Breakpoint Tables for Interpretation for MICs and Zone Diameters, Version 4.0. http://www.eucast.org/fileadmin/src/ media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint-table_v_4.0.pdf (1 March 2014, date last accessed).
18. Ambretti S, Gaibani P, Berlingeri A et al. Evaluation of phenotypic and genotypic approaches for the detection of class A and class B carbapenemases inEnterobacteriaceae. MicrobDrug Resist 2013; 19: 212-5.
19. Ambretti S, Gaibani P, Caroli F et al. A carbapenem-resistant Klebsiella pneumoniae isolate harboring KPC-1 from Italy. New Microbiol 2010; 33: 281-2.
20. Diancourt L, Passet V, Verhoef J et al. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol 2005; 43: 4178-82.
21. Cannatelli A, D'Andrea MM, Giani T et al. In vivo emergence of colistin resistance in Klebsiella pneumoniae producing KPC-type carbapenemase mediated by insertional inactivation of the PhoQ/PhoP mgrB regulator. Antimicrob Agents Chemother 2013; 57: 5521-6.
22. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001; 48 Suppl 1: 5-16. Erratum in: J Antimicrob Chemother 2002; 49: 1049.
23. Sopirala MM, Mangino JE, Gebreyes WA et al. Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54: 4678-83.
24. Markou N, Markantonis SL, Dimitrakis E et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008; 30: 143-51.
25. Rodvold KA, Gotfried MH, Cwik M et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58: 1221-9.
26. Hirsch EB, Guo B, Chang KT et al. Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. J Infect Dis 2013; 207: 786-93.
27. Albur M, Noel A, Bowker K et al. Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae. Antimicrob Agents Chemother 2012; 56: 3441-3.
28. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 2008; 47: 32-40.
29. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
30. Ozbek B, Sentürk A. Postantibiotic effects of tigecycline, colistin sulfate, and levofloxacin alone or tigecycline-colistin sulfate and tigecyclinelevofloxacin combinations against Acinetobacter baumannii. Chemotherapy 2010; 56: 466-71.
31. Lavigne JP, Bonnet R, Michaux-Charachon S et al. Post-antibiotic and post-β-lactamase inhibitor effects of ceftazidime plus sulbactam on extended-spectrum β-lactamase-producing Gram-negative bacteria. J Antimicrob Chemother 2004; 53: 616-9.
32. Capone A, Giannella M, Fortini D et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013; 19: 23-30.
33. Halaby T, Al Naiemi N, Kluytmans J et al. Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit. Antimicrob Agents Chemother 2013; 57: 3224-9.
34. Mammina C, Bonura C, Di Bernardo F et al. Ongoing spread of colistin-resistant Klebsiella pneumoniae in different wards of an acute general hospital, Italy, June to December 2011. Euro Surveill 2012; 17: pii:20248.
35. Sassera D, Comandatore F, Gaibani P et al. Comparative genomics of closely related strains of Klebsiella pneumoniae reveals genes possibly involved in colistin resistance. Ann Microbiol 2013; in press.
36. Qureshi ZA, Paterson DL, Potoski BA et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56: 2108-13.
37. Elemam A, Rahimian J, Doymaz M. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol 2010; 48: 3558-62.
38. Landman D, Georgescu C, Martin DA et al. Polymyxins revisited. Clin Microbiol Rev 2008; 21: 449-65.
39. Jamal MA, Rosenblatt JS, Hachem RY et al. Prevention of Gram-negative bacterial biofilm on minocycline/rifampicin impregnated catheters sequentially coated with chlorhexidine. Antimicrob Agents Chemother 2013; 58: 1179-82.
40. Yahav D, Farbman L, Leibovici L et al. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 2012; 18: 18-29.
41. Cai Y, Chai D, Wang R et al. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012; 67: 1607-15.
42. Li J, Rayner CR, Nation RL. Hetero-resistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50: 2946-50.